Reply to Letter on: “Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis”.

Reply to Letter on: “Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis”. J Crohns Colitis. 2018 Oct 29;: Authors: Balram B, Battat R, Al-Khoury A, D’Aoust J, Afif W, Bitton A, Lakatos PL, Bessissow T PMID: 30371761 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30371761?dopt=Abstract

Read More

Prognostic value of the burden of cytomegalovirus colonic reactivation evaluated by immunohistochemical staining in patients with active ulcerative colitis.

Prognostic value of the burden of cytomegalovirus colonic reactivation evaluated by immunohistochemical staining in patients with active ulcerative colitis. J Crohns Colitis. 2018 Oct 20;: Authors: Clos-Parals A, Rodríguez-Martínez P, Cañete F, Mañosa M, Ruiz-Cerulla A, Paúles MJ, Llaó J, Gordillo J, Fumagalli C, Garcia-Planella E, Ojanguren I, Cabré E, Guardiola J, Domènech E Abstract Background: Colonic cytomegalovirus (CMV) reactivation has been involved in steroid refractoriness in patients with active ulcerative colitis (UC). The benefits of antiviral therapy in this clinical setting are still under debate, but the burden of…

Read More

Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.

Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile. Inflamm Bowel Dis. 2018 Oct 12;: Authors: Lukin DJ, Lawlor G, Hudesman DP, Durbin L, Axelrad JE, Passi M, Cavaliere K, Coburn E, Loftus M, Jen H, Feathers A, Rosen MH, Malter LB, Swaminath A, IBD-ReMEdY Study (Research, Mentoring, Education New York) Abstract Background: Clostridium difficile infection (CDI) is common in patients with inflammatory bowel disease (IBD), often leading to diagnostic confusion and delays in IBD therapy escalation. This study sought…

Read More

Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting.

Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting. Inflamm Bowel Dis. 2018 Oct 12;24(11):2431-2441 Authors: Ng SC, Hilmi IN, Blake A, Bhayat F, Adsul S, Khan QR, Wu DC Abstract Background: Vedolizumab (ENTYVIO) is a humanized α4β7 integrin antagonist approved for the treatment of inflammatory bowel disease, which selectively blocks gut-specific lymphocyte trafficking. We evaluated the risk of opportunistic infections of interest in patients treated with vedolizumab. Methods: We determined the frequency of opportunistic infections and tuberculosis in patients receiving vedolizumab in phase…

Read More

Erratum to Increased Risk of Influenza and Influenza-Related Complications Among 140,480 Patients With Inflammatory Bowel Disease.

Erratum to Increased Risk of Influenza and Influenza-Related Complications Among 140,480 Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Oct 12;: Authors: Tinsley A, Navabi S, Williams ED, Liu G, Kong L, Coates MD, Clarke K PMID: 30312402 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30312402?dopt=Abstract

Read More

Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection.

Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection. Inflamm Bowel Dis. 2018 Sep 26;: Authors: Solanky D, Pardi DS, Loftus EV, Khanna S Abstract Background: Inflammatory bowel disease (IBD) is an independent risk factor for Clostridium difficile infection (CDI), and CDI often precipitates IBD exacerbation. Because CDI cannot be distinguished clinically from an IBD exacerbation, management is difficult. We aimed to assess factors associated with adverse outcomes in IBD with CDI, including the role of escalating or de-escalating IBD therapy…

Read More

Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Diseases Do Not Impact Serious Infections After Arthroplasty.

Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Diseases Do Not Impact Serious Infections After Arthroplasty. J Crohns Colitis. 2018 Sep 26;: Authors: Gregory MH, McKinnon A, Stwalley D, Hippensteel KJ, Loftus EV, Ciorba MA, Olsen MA, Deepak P Abstract Background and Aims: There is a paucity of data on the safety of joint replacement surgery in patients with inflammatory bowel disease (IBD), including those on tumor necrosis factor-alpha inhibitors (anti-TNF). We explored the risk of serious infections in this population. Methods: A retrospective case-control study (2006-2014) was performed using the…

Read More

Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis.

Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2018 Sep 21;: Authors: Balram B, Battat R, Al-Khoury A, D’Aoust J, Afif W, Bitton A, Lakatos PL, Bessissow T Abstract Background: Clostridium difficile Infection (CDI) is a significant concern in Inflammatory Bowel Disease (IBD). Risk factors and consequences associated with CDI in Inflammatory Bowel Disease (IBD) patients are important to characterize. Aim: To perform a systematic review and meta-analysis to assess risk factors and outcomes associated with CDI in IBD…

Read More
<< Go Back